BIOLOGICS USE IN CROHN’S DISEASE IN FRANCE
Author(s)
Gaudry J1, Morand F2, Willemin L3, Lee XY4, Lelli F5
1IMS Health, Boulogne-Billancourt, France, 2IMS Health, Paris La Défense, France, 3Janssen-Cilag, Issy-les-Moulineaux, France, 4Janssen-Cilag A/S, Birkerød, Denmark, 5Janssen-Cilag SpA, Cologno Monzese (MI), Italy
OBJECTIVES: Limited French real world data on Crohn’s disease (CD) patients treated with biologics is available. This study aims to describe the profile of French adult CD patients treated with biologics, treatment patterns, disease management, and biologic dosing patterns. METHODS: Two different sources of data reflecting clinical practice were used: a cross-sectional survey (Patient Database Survey-PDS) of 130 hospital-based hepato-gastroenterologists with data collected for CD patients treated by biologics between December 2015 and January 2016; an Electronic Medical Record(EMR) database with 100 office-based gastroenterologists and data collected over 12 months up to January 2016 for CD patients treated with adalimumab. RESULTS:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PGI32
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Gastrointestinal Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now